BHT Lifescience Australia

BHT Lifescience Australia is the regional subsidiary of BHT Lifescience, a specialized biotechnology and medical technology company focused on the development of Boron Neutron Capture Therapy (BNCT). The company's core offering is the NeuCure® system, an accelerator-based BNCT (AB-BNCT) platform designed to provide high-precision radiotherapy for difficult-to-treat cancers. By combining a high-flux neutron source with boron-10 carriers such as boronophenylalanine (BPA), the technology enables the selective destruction of tumor cells at the cellular level while minimizing damage to adjacent healthy tissue. BHT Lifescience is actively involved in clinical trials and the establishment of BNCT treatment centers globally to address indications like glioblastoma multiforme and recurrent head and neck cancers. The Australian entity supports the company's expansion and clinical research initiatives within the Oceania region.